Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022038
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on the revision of the non-public offering plan in 2022
The board of directors and all directors of the company guarantee that there are no false records and misleading statements in the contents of this announcement
Or major omissions, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) on 2022
On March 7, 2022, the fifth interim meeting and the fifth session of the Fifth Board of directors were held
At the fifth extraordinary meeting of the board of supervisors in 2022, the proposal on the company’s plan for non-public offering of shares in 2022 (Revised Draft) was reviewed and approved, and the company’s plan for non-public offering of shares in 2022 was revised. The main revisions are as follows:
Revision of sections of the plan
Section 2 this offering v. the issuing object and its directors, supervisors, and the controlling shareholders of the issuing object are supplemented
Basic information of the object: punishment and prosecution of senior managers in the last five years; punishment and prosecution of actual controllers in the last five years
Litigation situation
Plan for Hunan Fangsheng Pharmaceutical Co.Ltd(603998) 2022 non public offering of shares
(Revised Version) and relevant documents have been posted on the website of Shanghai Stock Exchange
（www.sse.com.cn.） Disclosure, please pay attention to the majority of investors. The effectiveness and completion of matters related to this non-public offering of shares are yet to be considered and approved by the general meeting of shareholders and approved by the China Securities Regulatory Commission. Please pay attention to the investment risks.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 7, 2022
